Abstract
Type 2 (non-insulin-dependent) diabetes mellitus afflicts millions of people worldwide and is one of the main causes of morbidity and mortality. Current therapeutic agents to treat Type 2 diabetes are insufficient and thus, newer approaches are desperately needed. Type 2 diabetes is manifested by progressive metabolic impairments in tissues such as skeletal muscle, adipose tissue and liver, such that these tissues become less responsive to insulin. Skeletal muscle is quantitatively the most important tissue involved in maintaining glucose homeostasis under insulin-stimulated conditions, and is a major site of insulin resistance in Type 2 diabetic patients. At the cellular level, glucose transport into skeletal muscle is the rate-limiting step for whole body glucose uptake and a primary site of insulin resistance in Type 2 diabetes. Thus, skeletal muscle is a key insulin target tissue that harbours intrinsic defects that impinges upon whole body glucose homeostasis. Here, we review the current knowledge of signalling events that regulate glucose transport in human skeletal muscle.
Keywords: adipose tissue, glucose transport, insulin resistance, insulin signalling, obesity, skeletal muscle, type (non-insulin dependent) diabetes mellitus
Current Diabetes Reviews
Title: Molecular Mechanisms of Skeletal Muscle Insulin Resistance in Type 2 Diabetes
Volume: 1 Issue: 2
Author(s): Karim Bouzakri, Heikki A. Koistinen and Juleen R. Zierath
Affiliation:
Keywords: adipose tissue, glucose transport, insulin resistance, insulin signalling, obesity, skeletal muscle, type (non-insulin dependent) diabetes mellitus
Abstract: Type 2 (non-insulin-dependent) diabetes mellitus afflicts millions of people worldwide and is one of the main causes of morbidity and mortality. Current therapeutic agents to treat Type 2 diabetes are insufficient and thus, newer approaches are desperately needed. Type 2 diabetes is manifested by progressive metabolic impairments in tissues such as skeletal muscle, adipose tissue and liver, such that these tissues become less responsive to insulin. Skeletal muscle is quantitatively the most important tissue involved in maintaining glucose homeostasis under insulin-stimulated conditions, and is a major site of insulin resistance in Type 2 diabetic patients. At the cellular level, glucose transport into skeletal muscle is the rate-limiting step for whole body glucose uptake and a primary site of insulin resistance in Type 2 diabetes. Thus, skeletal muscle is a key insulin target tissue that harbours intrinsic defects that impinges upon whole body glucose homeostasis. Here, we review the current knowledge of signalling events that regulate glucose transport in human skeletal muscle.
Export Options
About this article
Cite this article as:
Bouzakri Karim, Koistinen A. Heikki and Zierath R. Juleen, Molecular Mechanisms of Skeletal Muscle Insulin Resistance in Type 2 Diabetes, Current Diabetes Reviews 2005; 1 (2) . https://dx.doi.org/10.2174/1573399054022785
DOI https://dx.doi.org/10.2174/1573399054022785 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Benefits of L-Arginine on Cardiovascular System
Mini-Reviews in Medicinal Chemistry A Possible Placental Factor for Preeclampsia: sFlt-1
Current Medicinal Chemistry Intracoronary Brachytherapy - Clinical State and Pathophysiological Considerations
Current Pharmaceutical Design The Role of Recombinant Human Platelet-derived Growth Factor-BB (rhPDGF-BB) in Orthopaedic Bone Repair and Regeneration
Current Pharmaceutical Design Clinical Thiazolidinediones as PPARγ Ligands with the Potential for the Prevention of Cardiovascular Disease in Diabetes
Current Diabetes Reviews Anti-Oxidant Gene Therapy by NFkB Decoy Oligodeoxynucleotide
Current Pharmaceutical Biotechnology Low Osteopontin N-Terminal Fragment and Carotid Plaque Stability Associated with Statin or Antiplatelet Therapy
Current Vascular Pharmacology Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry First Comprehensive Analysis of Outcomes in Adult Patients after Percutaneous Closure of Isolated Secundum Atrial Septal Defects
Cardiovascular & Hematological Agents in Medicinal Chemistry Heme Oxygenase-Derived Carbon Monoxide Restores Vascular Function in Type 1 Diabetes
Drug Metabolism Letters Impacts of Nanoparticles on Cardiovascular Diseases: Modulating Metabolism and Function of Endothelial Cells
Current Drug Metabolism The VHL Tumor Suppressor: Master Regulator of HIF
Current Pharmaceutical Design Effects of Combining Linagliptin Treatment with BI-38335, A Novel SGLT2 Inhibitor, on Pancreatic Islet Function and Inflammation in db/db Mice
Current Molecular Medicine Extranuclear Localization of SIRT1 and PGC-1α: An Insight into Possible Roles in Diseases Associated with Mitochondrial Dysfunction
Current Molecular Medicine High Performance Liquid Chromatographic Approaches to Mass Spectrometry Based Metabolomics
Current Metabolomics Transcriptional Regulation of the Heme Oxygenase-1 Gene Via the Stress Response Element Pathway
Current Pharmaceutical Design Exploring Shared Pathogenesis of Alzheimer’s Disease and Type 2 Diabetes Mellitus via Co-expression Networks Analysis
Current Alzheimer Research Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication
Current Pharmaceutical Design Is Later Obesity Programmed In Utero?
Current Drug Targets Molecular Genetics and Epidemiology of Japanese Type 1 Diabetes
Current Pharmacogenomics